Can alcohol dependent patients adhere to an 'As-needed' medication regimen?

European Addiction Research

Volumn 20, Issue 5, 2014, Pages 209-217

  Sinclair, Julia ^a   Chick, Jonathan ^b   Sørensen, Per ^c   Kiefer, Falk ^d   Batel, Philippe ^e   Gual, Antoni ^f  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b QUEEN MARGARET UNIVERSITY   (United Kingdom)

^c H LUNDBECK A S   (Denmark)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f HOSPITAL CLÍNIC   (Spain)

Author keywords

Alcohol dependence; As needed regimen; Nalmefene; Self management

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; NALMEFENE; PLACEBO; NALTREXONE; NARCOTIC ANTAGONIST;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DRUG USE; FEASIBILITY STUDY; FEMALE; HELP SEEKING BEHAVIOR; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICATION COMPLIANCE; MIDDLE AGED; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION; ANALOGS AND DERIVATIVES; SELF CARE; TREATMENT OUTCOME;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; SELF CARE; TREATMENT OUTCOME;

EID: 84895666268     PISSN: 10226877     EISSN: 14219891     Source Type: Journal    
DOI: 10.1159/000357865     Document Type: Article

References (40)

1. McKay JR, Hiller-Sturmhofel S: Treating alcoholism as a chronic disease. Approaches to long-term continuing care. Alcohol Res Health 2011; 33: 356-370.
2. Schuckit MA: Alcohol-use disorders. Lancet 2009; 373: 492-501.
3. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J, Barker-Collo S, Baxter A, Bell ML, Blore JD, Blyth F, Bonner C, Borges G, Bourne R, Boussinesq M, Brauer M, Brooks P, Bruce NG, Brunekreef B, Bryan-Hancock C, Bucello C, Buchbinder R, Bull F, Burnett RT, Byers TE, Calabria B, Carapetis J, Carnahan E, Chafe Z, Charlson F, Chen H, Chen JS, Cheng AT, Child JC, Cohen A, Colson KE, Cowie BC, Darby S, Darling S, Davis A, Degenhardt L, Dentener F, Des Jarlais DC, Devries K, Dherani M, Ding EL, Dorsey ER, Driscoll T, Edmond K, Ali SE, Engell RE, Erwin PJ, Fahimi S, Falder G, Farzadfar F, Ferrari A, Finucane MM, Flaxman S, Fowkes FG, Freedman G, Freeman MK, Gakidou E, Ghosh S, Giovannucci E, Gmel G, Graham K, Grainger R, Grant B, Gunnell D, Gutierrez HR, Hall W, Hoek HW, Hogan A, Hosgood HD 3rd, Hoy D, Hu H, Hubbell BJ, Hutchings SJ, Ibeanusi SE, Jacklyn GL, Jasrasaria R, Jonas JB, Kan H, Kanis JA, Kassebaum N, Kawakami N, Khang YH, Khatibzadeh S, Khoo JP, Kok C, Laden F, Lalloo R, Lan Q, Lathlean T, Leasher JL, Leigh J, Li Y, Lin JK, Lipshultz SE, London S, Lozano R, Lu Y, Mak J, Malekzadeh R, Mallinger L, Marcenes W, March L, Marks R, Martin R, McGale P, Mc-Grath J, Mehta S, Mensah GA, Merriman TR, Micha R, Michaud C, Mishra V, Mohd Hanafiah K, Mokdad AA, Morawska L, Mozaffarian D, Murphy T, Naghavi M, Neal B, Nelson PK, Nolla JM, Norman R, Olives C, Omer SB, Orchard J, Osborne R, Ostro B, Page A, Pandey KD, Parry CD, Passmore E, Patra J, Pearce N, Pelizzari PM, Petzold M, Phillips MR, Pope D, Pope CA 3rd, Powles J, Rao M, Razavi H, Rehfuess EA, Rehm JT, Ritz B, Rivara FP, Roberts T, Robinson C, Rodriguez-Portales JA, Romieu I, Room R, Rosenfeld LC, Roy A, Rushton L, Salomon JA, Sampson U, Sanchez-Riera L, Sanman E, Sapkota A, Seedat S, Shi P, Shield K, Shivakoti R, Singh GM, Sleet DA, Smith E, Smith KR, Stapelberg NJ, Steenland K, Stockl H, Stovner LJ, Straif K, Straney L, Thurston GD, Tran JH, Van Dingenen R, van Donkelaar A, Veerman JL, Vijayakumar L, Weintraub R, Weissman MM, White RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams W, Wilson N, Woolf AD, Yip P, Zielinski JM, Lopez AD, Murray CJ, Ezzati M, AlMazroa MA, Memish ZA: A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013; 380: 2224-2260.
4. Rehm J: The risks associated with alcohol use and alcoholism. Alcohol Res Health 2011; 34: 135-143.
5. Davis A, Rosenberg H: Acceptance of nonabstinence goals by addiction professionals in the United States. Psychol Addict Behav 2013; 27: 1102-1109.
6. Gastfriend DR, Garbutt JC, Pettinati HM, Forman RF: Reduction in heavy drinking as a treatment outcome in alcohol dependence. J Subst Abuse Treat 2007; 33: 71-80.
7. Klingemann H, Rosenberg H: Acceptance and therapeutic practice of controlled drinking as an outcome goal by Swiss alcohol treatment programmes. Eur Addict Res 2009; 15: 121-127.
8. Luquiens A, Reynaud M, Aubin HJ: Is controlled drinking an acceptable goal in the treatment of alcohol dependence? A survey of French alcohol specialists. Alcohol Alcohol 2011; 46: 586-591.
9. Maisto SA, Clifford PR, Stout RL, Davis CM: Moderate drinking in the first year after treatment as a predictor of three-year outcomes. J Stud Alcohol Drugs 2007; 68: 419-427.
10. Witkiewitz K: 'Success' following alcohol treatment: moving beyond abstinence. Alcohol Clin Exp Res 2013; 37(suppl 1):E9-E13.
11. Kline-Simon AH, Falk DE, Litten RZ, Mertens JR, Fertig J, Ryan M, Weisner CM: Posttreatment low-risk drinking as a predictor of future drinking and problem outcomes among individuals with alcohol use disorders. Alcohol Clin Exp Res 2013; 37(suppl 1): E373-E380.
12. National Institute for Health and Clinical Excellence: Clinical Guideline 115. Alcohol-use disorders. Diagnosis, assessment and treatment of harmful drinking and alcohol dependence. February 2011. http://www.nice.org. uk/nicemedia/live/13337/53191/53191.pdf.
13. Rosner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M: Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010; 12:CD001867.
14. Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M: Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010; 9:CD004332.
15. Swift R, Oslin DW, Alexander M, Forman R: Adherence monitoring in naltrexone pharmacotherapy trials: a systematic review. J Stud Alcohol Drugs 2011; 72: 1012-1018.
16. Bodenheimer T, Lorig K, Holman H, Grumbach K: Patient self-management of chronic disease in primary care. JAMA 2002; 288: 2469-2475.
17. Coleman M, Newton K: Supporting self-management in patients with chronic illness. Am Fam Physician 2005; 72: 1503-1510.
18. Heinala P, Alho H, Kiianmaa K, Lonnqvist J, Kuoppasalmi K, Sinclair JD: Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol 2001; 21: 287-292.
19. Hernandez-Avila CA, Song C, Kuo L, Tennen H, Armeli S, Kranzler HR: Targeted versus daily naltrexone: secondary analysis of effects on average daily drinking. Alcohol Clin Exp Res 2006; 30: 860-865.
20. Kranzler HR, Tennen H, Armeli S, Chan G, Covault J, Arias A, Oncken C: Targeted naltrexone for problem drinkers. J Clin Psychopharmacol 2009; 29: 350-357.
21. Mann K, Bladstrom A, Torup L, Gual A, Van Den Brink W: Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed Nalmefene. Biol Psychiatry 2013; 73: 706-713.
22. Gual A, He Y, Torup L, Van Den Brink W, Mann K; ESENSE 2 Study Group: A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. Eur Neuropsychopharmacol 2013; 23: 1432-1442.
23. Van Den Brink W, Aubin HJ, Bladstrom A, Torup L, Gual A, Mann K: Efficacy of asneeded nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol Alcohol 2013; 48: 570-578.
24. Bart G, Schluger J, Borg L, Ho A, Bidlack J, Kreek M: Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology 2005; 30: 2254-2262.
25. Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E: A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 1994; 18: 1162-1167.
26. Ingman K, Hagelberg N, Aalto S, Nagren K, Juhakoski A, Karhuvaara S, Kallio A, Oikonen V, Hietala J, Scheinin H: Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology 2005; 30: 2245-2253.
27. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders 4th edition ext Revision (DSM-IV-TR). Washington, American Psychiatric Association, 2000.
28. European Medicines Agency: Guideline on the development of medicinal products for the treatment of alcohol dependence. EMEA/CHMP/EWP/20097/2008. http://www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/03/WC500074898. pdf.
29. World Health Organization: International guide for monitoring alcohol consumption and related harm 2010; WHO/MSD/MSB/00.4. http://whqlibdoc.who.int/hq/2000/who-msd-msb-00.4.pdf.
30. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM: Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989; 84: 1353-1357.
31. Sobell LC, Sobell MB: Timeline follow-back: a technique for assessing self-reported ethanol consumption; in Litten RZ, Allen JP (eds): Measuring Alcohol Consumption: Psychosocial and Biological Methods. Totowa, Humana Press, 1992.
32. Starosta A, Leeman R, Volpicelli J: The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders. J Psychiatr Pract 2006; 12: 80-89.
33. Haynes RB, Devereaux PJ, Guyatt GH: Physicians' and patients' choices in evidence based practice. BMJ 2002; 324: 1350.
34. Barlow J, Wright C, Sheasby J, Turner A, Hainsworth J: Self-management approaches for people with chronic conditions: a review. Patient Educ Couns 2002; 48: 177-187.
35. Lee Y, Lin JL: Do patient autonomy preferences matter? Linking patient-centered care to patient-physician relationships and health outcomes. Soc Sci Med 2010; 71: 1811-1818.
36. Baker E, Fee F, Bovingdon L, Campbell T, Hewis E, Lewis D: From taking to using medication: recovery-focused prescribing and medicines management. Adv Psych Treatment 2013; 19: 2-10.
37. Karhuvaara S, Simojoki K, Virta A, Rosberg M, Loyttyniemi E, Nurminen T, Kallio A, Makela R: Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol Clin Exp Res 2007; 31: 1179-1187.
38. Leeman R, Palmer R, Corbin W, Romano D, Meandzija B, O'Malley S: A pilot study of naltrexone and BASICS for heavy drinking young adults. Addict Behav 2008; 33: 1048-1054.
39. Pound P, Britten N, Morgan M, Yardley L, Pope C, Daker-White G, Campbell R: Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med 2005; 61: 133-155.
40. Kohn R, Saxena S, Levav I, Saraceno B: The treatment gap in mental health care. Bull World Health Organ 2004; 82: 858-866.